One Pager as on February 29, 2024
Rule based diversification for optimum performance in changing market cycles | |
Aim to provide stability of large caps and growth of mid caps | |
Active stock selection through internal process framework for better return potential | |
Sector | MMLMCF | NIFTY Large Midcap 250 TRI Index |
Financial Services | 18.31% | 26.41% |
Oil Gas & Consumable Fuels | 12.45% | 7.70% |
Healthcare | 10.72% | 7.63% |
Capital Goods | 10.70% | 7.39% |
Information Technology | 10.10% | 9.46% |
Data as on February 29, 2024
Security | % to Net Assets |
Coal India Limited | 4.17% |
Canara Bank | 4.01% |
Hindustan Petroleum Corporation Limited | 3.90% |
Larsen & Toubro Limited | 3.10% |
The Jammu & Kashmir Bank Limited | 2.52% |
NTPC Limited | 2.49% |
Tata Power Company Limited | 2.41% |
NMDC Limited | 2.29% |
ACC Limited | 2.22% |
NBCC (India) Limited | 2.10% |
Total | 29.21% |
Fresh Additions | Complete Exits |
Security | Security |
Biocon Limited | IndusInd Bank Limited |
Max Healthcare Institute Limited | MphasiS Limited |
State Bank of India | One 97 Communications Limited |
Tata Consultancy Services Limited | RBL Bank Limited |
SJVN Limited |
Note: The companies/stock(s) referred above are only for the purpose of disclosure of significant portfolio
changes during the month and should not be construed as recommendation to buy/sell/ hold. The fund manager
may or may not choose to hold these companies/stocks, from time to time. Investors are requested to consult
their financial, tax and other advisors before taking any investment decision(s). Data as on February 29, 2024
Turnover Ratio (Last 1 year) | 1.31 |
Standard Deviation | 13.50% |
Beta | 0.95 |
Sharpe Ratio# | 1.17 |
Jenson's Alpha | 0.1642 |
#Risk-free rate assumed to be 6.80% (MIBOR as on 29-02-24) - Source: www.mmda.org
Note: As per AMFI guidelines for factsheet, the ratios are calculated based on month rolling returns
for last 3 years. Data as on February 29, 2024
^Benchmark ^^Additional Benchmark. CAGR – Compounded Annual Growth Rate. Inception/Allotment date: 30-Dec-19.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments. Since inception returns of the scheme is calculated on face value of Rs. 10 invested at inception. The performance details provided above are
of Growth Option under Regular Plan. Different Plans i.e Regular Plan and Direct Plan under the scheme has different expense structure. *Based on standard investment of Rs. 10,000 made at the
beginning of the relevant period. Mr. Manish Lodha is managing this scheme since December 21, 2020. Mr. Abhinav Khandelwal is managing this scheme since February 1, 2022.
^Benchmark ^^Additional Benchmark. CAGR – Compounded Annual Growth Rate. Inception/Allotment date: 30-Dec-19.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments. Returns greater than 1 year period are compounded annualized. For SIP returns, monthly investment of equal amounts invested on the 1st business day
of every month has been considered. CAGR Returns (%) are computed after accounting for the cash flow by using the XIRR method (investment internal rate of return).
^Benchmark CAGR – Compounded Annual Growth Rate. $Dedicated Fund Manager for Overseas Investments.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments. The performance details provided above are of
Growth Option under Regular Plan Different Plans i.e Regular Plan and Direct Plan under the scheme has different expense structure. Mr. Manish Lodha is managing 10 schemes and
Mr. Abhinav Khandelwal is managing 6 schemes of Mahindra Manulife Mutual Fund. The performance data for the schemes which have not completed one year has not been provided.
Performance as on February 29, 2024
This product is suitable for investors who are seeking*:
• Long term wealth creation and
income;
• Investment predominantly in equity
and equity related securities of large
and mid cap companies.
*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.